A Study of LY2835219 in Healthy Participants

Completed · Phase 1

Conditions studied: Healthy Volunteers

In brief

The aim of this two-period study is to compare how much of the study drug gets into the blood stream when it is given as a single oral dose and when it is given as a single oral dose in combination with rifampin (a Food and Drug Administration \[FDA\] approved antibiotic that is used to treat tuberculosis, a bacterial infection that mainly affects the lungs, and other infections). Each participant will complete both study periods. The study will last about 34 days. Screening is required within 28 days before study drug is given.

Key facts

Study ID
NCT02256267
Run by
Eli Lilly and Company
People needed
24
Starts
2014-10-01
Expected to finish
2014-11-01
Last updated by the study team
2019-01-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.